Development of a tumor-selective approach to treat metastatic cancer

Area of Science:

• Oncology
• Stem Cell Biology
• Gene Therapy

Background:

• Metastatic cancer presents a poor prognosis with limited curative treatment options.
• Current therapies for disseminated disease are often not curative and cause significant side effects.
• Developing tumor-selective treatments is crucial for maximizing therapeutic benefits and minimizing toxicity.

Purpose of the Study:

• To investigate the potential of exploiting the tumor-tropic properties of stem cells for targeted cancer therapy.
• To test if engineered stem cells can selectively deliver therapeutic genes to metastatic solid tumors.
• To evaluate the efficacy of this approach in mediating cures for metastatic disease.

Main Methods:

• Stem cells (HB1.F3.C1) were genetically modified to express an enzyme that activates the anti-cancer prodrug CPT-11.
• These engineered cells were intravenously injected into mice with disseminated neuroblastoma tumors.
• Mice received systemic CPT-11 treatment, and tumor response was monitored.

Main Results:

• Engineered HB1.F3.C1 stem cells demonstrated selective migration to tumor sites, irrespective of tumor size or location.
• Mice treated with the combination of engineered stem cells and CPT-11 achieved 100% tumor-free survival for over six months.
• This outcome was statistically significant compared to control groups (P<0.001).

Conclusions:

• Stem or progenitor cells possess tumor-tropic properties that can be leveraged for effective, tumor-selective therapy.
• This novel approach offers a promising strategy for treating metastatic tumors where curative treatments are currently lacking.
• The findings suggest a potential paradigm shift in managing advanced cancers.